The present invention discloses a new metal cyano-substituted benzimidazolide salt having formula (I) and its preparation. This new cyano-substituted benzimidazole derivatives exhibited excellent thermal stability. The organic salt of the present invention were soluble in an alkyl carbonate solvent, such as propylene carbonate (PC), dimethyl carbonate (DMC) and ethylene carbonate (EC)/DMC cosolvent. The non-aqueous electrolyte prepared by mixing the organic metal salt of the present invention with the alkyl carbonate solvent shows high conductivity and excellent electrochemical stability. The non-aqueous electrolyte is suitable for use in primary or secondary rechargeable batteries. ##STR00001##

The present invention provides a novel heterocyclic derivative or a pharmaceutically acceptable salt thereof. For example, the present invention provides a heterocyclic derivative of the general formula [1] or its tautomer, or a pharmaceutically acceptable salt thereof: ##STR00001##
wherein R.sup.1 and R.sup.2 are the same or different aromatic rings, etc., and ring A is a heterocyclic ring. The compound of the invention or a pharmaceutically acceptable salt thereof has potent mPGES-1 inhibiting activity and is useful as an agent for the treatment or prevention of a disease, such as rheumatoid arthritis, osteoarthritis, temporomandibular joint disorders, low back pain, endometriosis, dysmenorrhea, overactive bladder, malignant tumors or neurodegenerative disease.

The present invention provides a novel heterocyclic derivative or a pharmaceutically acceptable salt thereof. For example, the present invention provides a heterocyclic derivative of the general formula [1] or its tautomer, or a pharmaceutically acceptable salt thereof: ##STR00001##
wherein R.sup.1 and R.sup.2 are the same or different aromatic rings, etc., and ring A is a heterocyclic ring. The compound of the invention or a pharmaceutically acceptable salt thereof has potent mPGES-1 inhibiting activity and is useful as an agent for the treatment or prevention of a disease, such as rheumatoid arthritis, osteoarthritis, temporomandibular joint disorders, low back pain, endometriosis, dysmenorrhea, overactive bladder, malignant tumors or neurodegenerative disease.

The invention relates to compounds of formula I, or a pharmaceutically-acceptable salt thereof. The present invention also relates to pharmaceutical formulations comprising these compounds, and to their use as medicaments for the treatment of disorders where modulation of DCTPP (deoxycytidine triphosphate pyrophosphatase 1) activity exerts a therapeutic effect.

##STR00001##

The invention relates to compounds of formula I, or a pharmaceutically-acceptable salt thereof. The present invention also relates to pharmaceutical formulations comprising these compounds, and to their use as medicaments for the treatment of disorders where modulation of DCTPP (deoxycytidine triphosphate pyrophosphatase 1) activity exerts a therapeutic effect.

##STR00001##

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I) Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. ##STR00001##

Provided are novel compounds of Formulas (I) and (II), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful as dual FKBP12/FKABP inhibitors. Also provided are pharmaceutical compositions comprising the novel compounds of Formulas (I) and (II) and their use in treating Parkinson's disease.

##STR00001##

Provided are novel compounds of Formulas (I) and (II), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful as dual FKBP12/FKABP inhibitors. Also provided are pharmaceutical compositions comprising the novel compounds of Formulas (I) and (II) and their use in treating Parkinson's disease.

##STR00001##

The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I′): where the substituents R, R.sup.1, R.sup.3 R.sup.4, R′, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues. ##STR00001##

The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I′): where the substituents R, R.sup.1, R.sup.3 R.sup.4, R′, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues. ##STR00001##